Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 3/20 | 0.44 |
| ▸ | FLT4 | P35916 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | CCR9 | P51686 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1206953 | 0.83 | FLT1 (0.61) | FLT1FLT4KDRPPARD | |
| SCHEMBL1207427 | 0.76 | FLT1 (0.44) | FLT1FLT4KDRALDH1A1MAPT | |
| SCHEMBL1206964 | 0.76 | FLT1 (0.40) | FLT1FLT4KDRCCR9L3MBTL1 | |
| SCHEMBL1206930 | 0.76 | PDE4B (0.39) | FLT1FLT4KDRCCR9ALDH1A1 | |
| SCHEMBL4372091 | 0.74 | FLT1 (0.43) | FLT1FLT4KDRALDH1A1LMNA | |
| SCHEMBL27640889 | 0.73 | CASP1 (0.46) | NTRK1ALDH1A1HPGDKDM1AJAK2 | |
| SCHEMBL1206402 | 0.73 | FLT1 (0.46) | FLT1FLT4KDRALDH1A1LMNA | |
| SCHEMBL4373803 | 0.72 | L3MBTL1 (0.46) | CCR9L3MBTL1ALDH1A1LMNAMAPT | |
| SCHEMBL4370293 | 0.72 | KMT2A (0.47) | CCR9L3MBTL1ALDH1A1LMNA | |
| SCHEMBL4370332 | 0.71 | L3MBTL1 (0.46) | CCR9L3MBTL1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879884-B2 | 6-(2-Chloro-phenyl)-5-methyl-pyridine-3-sulfonic acid 2-chloro-4-fluoro-benzoylamide; potassium salt, used as antiproliferative, anticarcinogenic or antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2011-02-01 | — | — | US | claimed |
| US-20100256200-A1 | ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-07 | — | — | US | claimed |
| EP-2148861-A1 | ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-Roche AG (CH) | 2010-02-03 | — | — | EP | claimed |
| WO-2008138594-A1 | ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-20 | — | — | WO | claimed |
| US-7879884-B2 | 6-(2-Chloro-phenyl)-5-methyl-pyridine-3-sulfonic acid 2-chloro-4-fluoro-benzoylamide; potassium salt, used as antiproliferative, anticarcinogenic or antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100256200-A1 | ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-07 | — | — | US | disclosed |
| EP-2148861-A1 | ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-Roche AG (CH) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008138594-A1 | ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256200-A1 | ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | ARSA, STS, SULT2A1 | FLT1 2946/4885FLT4 3444/4885KDR 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.